siRNA: A new approach to target neuropathic pain

BioDrugs

Volumn 26, Issue 6, 2012, Pages 401-412

  Kaur, Indu Pal ^a   Sharma, Gaurav ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Drug delivery systems; Neuropathic pain; RNAi; Small interfering RNA

Indexed keywords

BETA ARRESTIN 2; BETA ENDORPHIN; DELTA OPIATE RECEPTOR; ENDOMORPHIN 2; GELATINASE A; GELATINASE B; GLUTAMATE DECARBOXYLASE 67; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROENKEPHALIN; PROPROTEIN CONVERTASE SUBTILISN KEXIN TYPE 9; PROSTAGLANDIN E RECEPTOR 4; PROTEIN; PROTEIN KINASE C GAMMA; PURINERGIC P2X3 RECEPTOR; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; SODIUM CHANNEL NAV1.8; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ALLODYNIA; ANALGESIA; CHRONIC PAIN; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HYPERALGESIA; INFLAMMATORY PAIN; MOLECULAR PATHOLOGY; NEUROPATHIC PAIN; NONHUMAN; PAIN RECEPTOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEURALGIA; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84868103396     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11634380-000000000-00000     Document Type: Review

References (89)

1. Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol 2006; 2006: 1-15
2. Marta LF, Tamara M, Ana J.RNAinterference technologies and therapeutics: From basic research to products. Biodrugs 2009; 23: 305-32
3. Tiemann K, Rossi JJ. RNAi-based therapeutics: Current status, challenges and prospects. EMBO Mol Med 2009; 1: 142-51
4. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-84
5. Geusens B, Sanders N, Prow T, et al. Cutaneous short-interfering RNA therapy. Expert Opin Drug Deliv 2009; 6: 1333-49
6. Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-6 (Pubitemid 32151243)
7. Hammond SM, Bernstein E, BeachD, et al. AnRNA-directed nucleasemediates post-transcriptional gene silencing in drosophila cells. Nature 2000; 404: 293-6 (Pubitemid 30163547)
8. Angaji SA, Hedayati SS, Poor RH. Application of RNA interference in treating human diseases. J Genet 2010; 89: 1-11
9. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004; 351: 1772-7
10. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Drug Discov 2002; 3: 737-47
11. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009; 10: 126-39
12. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006; 126: 231-5 (Pubitemid 44092975)
13. Anesti AM, Coffin RS. Delivery of RNA interference triggers to sensory neurons in vivo using herpes simplex virus. Expert Opin Biol Ther 2010; 10: 89-103
14. Leung RKM, Whittaker PA. RNA interference: From gene silencing to genespecific therapeutics. Pharmacol Ther 2005; 107: 222-39 (Pubitemid 40910042)
15. AlnylamPharmaceuticals.Alnylamreports positive clinical results forALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia [online].Available fromURL:http://phx.corporate-ir.net/ phoenix. zhtml?c=148005&p=irol-newsArticle&ID=1685443&highlight= [Accessed 2012 Apr 01]
16. Trehan S, Sharma G, Misra A. siRNA: Sojourn from discovery to delivery challenges and clinics. Syst Rev Pharm 2010; 1: 1-16
17. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci 2001; 2: 83-91 (Pubitemid 33673362)
18. Dray A. Neuropathic pain: Emerging treatments. Br J Anaesth 2008; 101: 48-58 (Pubitemid 351881912)
19. Jain KK. Gene therapy for pain. Expert Opin Biol Ther 2008; 8: 1855-66
20. Kinloch RA, Cox PJ. New targets for neuropathic pain therapeutics. Expert Opin Ther Targets 2005; 9: 685-98 (Pubitemid 41131673)
21. Carpenter K, Dickenson A. Molecular aspects of pain research. Pharmacogenomics J 2002; 2: 87-95 (Pubitemid 34982211)
22. Siniscalco D, de Novellis V, Rossi F, et al. Neuropathic pain: Is the end of suffering starting in the gene therapy? Curr Drug Targets 2005; 6: 75-80 (Pubitemid 40394325)
23. Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell 2009; 139: 267-84
24. Gunju P, Hall J. Potantial application of siRNA for pain therapy. Expert Opin Biol Ther 2004; 4: 531-42 (Pubitemid 38480552)
25. Savard LD, Roussy G, Dansereau MA, et al. Central delivery of dicersubstrate siRNA: A direct application for pain research. Mol Ther 2008; 16: 1331-9 (Pubitemid 351866066)
26. Luo MC, Zhang DQ, Ma SW, et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain 2005; 1: 1-8
27. Dorn G, Patel S, Wotherspoon G, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004; 32: E49
28. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006 Jan; 11: 67-73 (Pubitemid 43227854)
29. Kim H, Clark D, Dionne RA. Genetic contributions to clinical pain and analgesia: Avoiding pitfalls in genetic research. J Pain 2009; 10: 663-93
30. Dray A. Novel molecular targets in pain control. Curr Opin Anaesthesiol 2003; 16: 521-5 (Pubitemid 37297290)
31. Tan P, Yang L, Shih H, et al. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 2005; 12: 59-66 (Pubitemid 40090045)
32. Christoph T, Grunweller A, Mika J, et al. Silencing of vanilloid receptor TRPV1 by RNAi reducesneuropathic and visceral pain in vivo. Biochem Biophys Res Commun 2006; 350: 238-43 (Pubitemid 44466599)
33. Christoph T, Bahrenberg G, Vry JD, et al. Investigation of TRPV1 loss-offunction phenotypes in transgenic shRNA expressing and knockout mice. Mol Cell Neurosci 2008; 37: 579-89
34. Trevisani M, Smart D, Gunthorpe MJ, et al. Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci 2002; 5: 546-51 (Pubitemid 34568996)
35. Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007; 6: 357-72 (Pubitemid 46705200)
36. Caterina M, Julius D. The vanilloid receptor: A molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24: 487-517 (Pubitemid 32695237)
37. Wolfe D, Hao S, Hu J, et al. Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 2007; 133: 29-38 (Pubitemid 350138306)
38. Joshi NK, Szallasi A. TRPV1 antagonists: The challenges for therapeutic targeting. Cell 2008; 15: 14-22
39. Trevisani M, Szallasi A. Targeting TRPV1: Challenges and issues in pain management. Open Drug Disc J 2010; 2: 37-49
40. Ritprajak P, Hashiguchi M, Azuma M. Topical application of creamemulsified cd86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells. Mol Ther 2008; 16: 1323-30 (Pubitemid 351866065)
41. Ruangsri S, Lin A, Mulpuri Y, et al. Relationship of axonal voltage-gated sodium channel 1.8 (NaV1.8) mRNA accumulation to sciatic nerve injuryinduced painful neuropathy in rats. J Biol Chem 2011; 286: 39836-47
42. Kasama S, Kawakubo M, Suzuki T, et al. RNA interference-mediated knockdown of transient receptor potential vanilloid 1 prevents forepaw inflammatory hyperalgesia in rat. Eur J Neurosci 2007; 25: 2956-63 (Pubitemid 46888823)
43. Jarvis MF, Kowaluk E. Pharmacological characterization of P2•3 homomeric and heteromeric channels in nociceptive signaling and behaviour. Drug Dev Res 2001; 52: 220-31 (Pubitemid 32401944)
44. Dong XW, Goregoaker S, Engler H, et al. Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats.Neuroscience 2007; 146: 812-21 (Pubitemid 46628998)
45. WuFX, Bian JJ, Miao XR, et al. Intrathecal siRNA against Toll-like receptor 4 reduces nociception in a rat model of neuropathic pain. Int J Med Sci 2010; 7: 251-9
46. Laube B, Kuhse j, Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 1998; 18: 2954-61 (Pubitemid 28163225)
47. Garraway SM, Xu Q, Inturrisi CE. Design and evaluation of small interfering RNAs that target expression of the N-methyl-D-Aspartate receptor NR1 subunit gene in the spinal cord dorsal horn. J Pharmacol Exp Ther 2007; 322: 982-8 (Pubitemid 47295812)
48. Garraway SM, Xu Q, Inturrisi CE. siRNA-mediated knockdown of the NR1 subunit gene of the NMDA receptor attenuates formalin-induced pain behaviors in adult rats. J Pain 2009; 10: 380-90
49. Kima Y, Cho H, Ahn YJ, et al. Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models. Pain 2012; 153: 1022-9
50. Qu X, Cai J, Li M, et al. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp Neurol 2009; 215: 298-307
51. Boyce S, Wyatt A, Webb JK, et al. Selective NMDANR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999; 38: 611-23 (Pubitemid 29150316)
52. Kao JH, Huang EYK, Tao PL. NR2B subunit of NMDA receptor at nucleus accumbens is involved in morphine rewarding effect by siRNA study. Drug Alcohol Depend 2011; 118: 366-74
53. Yang CH, Huang HW, Chen KH, et al. Antinociceptive potentiation and attenuation of tolerance by intrathecal b-Arrestin 2 small interfering RNA in rats. Br J Anaesth 2011; 107: 774-81
54. Velá zquez K, Mohammad H, Sweitzer SM. Protein kinase C in pain: Involvement of multiple isoforms. Pharmacol Res 2007; 55: 578-89 (Pubitemid 46962305)
55. Zou W, Song Z, Guo Q, et al. Intrathecal lentiviral- mediatedRNAinterference targeting PKCg attenuates chronic constriction injury-induced neuropathic pain in rats. Hum Gene Ther 2011; 22: 465-75
56. Zou W, Zhan X, Li M, et al. Identification of differentially expressed proteins in the spinal cord of neuropathic pain models with PKCgamma silence by proteomic analysis. Brain Res 2012; 1440: 34-46
57. Liu S, Yang J, Wang L, et al. Tibia tumor-induced cancer pain involves spinal p38 mitogen-Activated protein kinase activation via TLR4-dependent mechanisms. Brain Res 2010; 1346: 213-23
58. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NFjB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007; 355: 728-33 (Pubitemid 46330212)
59. Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 2007; 3: 1-9
60. Tas SW, Vervoordeldonk MJBM, Tak PP. Gene therapy targeting nuclear factor-B: Towards clinical application in inflammatory diseases and cancer. Curr Gene Ther 2009; 9: 160-70
61. Niederberger E, Geisslinger G. The IKK-NF-B pathway: A source for novel molecular drug targets in pain therapy? FASEB J 2008; 22: 3432-42
62. Lianxu C, Hongti J, Changlong Y. NF-kBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1b-induced and TNF-A-induced chondrocytes. Osteoarthritis Cartilage 2006; 14: 367-76 (Pubitemid 44268926)
63. Sun T, Luo J, Jia M, et al. Small interfering RNA-mediated knockdown of NF-kBp65 attenuates neuropathic pain following peripheral nerve injury in rats. Eur J Pharmacol 2012; 682: 79-85
64. Dohi T, Morita K, Kitayama T, et al. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol Ther 2009; 123: 54-79
65. Morita K, Motoyama N, Kitayama T, et al. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther 2008; 326: 633-45
66. Takahashi T, Aoki Y, Okubo K, et al. Upregulation of Cav3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. Pain 2010; 150: 183-91
67. Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008; 14: 331-6 (Pubitemid 351347915)
68. Hao S, Mata M, Glorioso JC, et al. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain 2006; 2: 1-9
69. Vit JP, Ohara PT, Bhargava A, et al. Silencing the Kir4.1 potassium channel subunit in satellite glial cells of the rat trigeminal ganglion results in pain-like behavior in the absence of nerve injury. J Neurosci 2008; 28: 4161-71
70. Peng X-m, Zhou Z-g, Glorioso JC, et al. Tumor necrosis factor-A contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol 2006; 59: 843-51 (Pubitemid 43673162)
71. Liu J, Wolfe D, Hao S, et al. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 2004; 10: 57-66 (Pubitemid 38878149)
72. Goss J, Harley C, Mata M, et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol 2002; 52: 662-5 (Pubitemid 35246874)
73. Finegold A, Mannes A, Iadarola M. A paracrine paradigm for in vivo gene therapy in the central nervous system: Treatment of chronic pain. Hum Gene Ther 1999; 10: 1251-7 (Pubitemid 29231867)
74. Deval E, Noel J, Lay N, et al. ASIC3, a sensor of acidic and primary inflammatory pain. EMBO J 2008; 27: 3047-55
75. Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv 2011; 8: 521-36
76. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 2009; 8: 129-38
77. Geusens B, Strobbe T, Bracke S, et al. Lipid-mediated gene delivery to the skin. Eur J Pharm Sci 2011; 43: 199-211
78. Hickerson RP, Vlassov AV, Wang Q, et al. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 2008; 18: 345-54 (Pubitemid 352791342)
79. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of shortinterfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A 2002; 99: 6047-52 (Pubitemid 34493262)
80. Donze O, Picard D. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 2002; 30: E46
81. Paddison PJ, Caudy AA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16: 948-58 (Pubitemid 34408544)
82. Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001; 107: 309-21 (Pubitemid 33049975)
83. Yang D. Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2002; 99: 9942-7 (Pubitemid 34831152)
84. Dinesh LK, Clarke AR. Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Adv Drug Deliv Rev 2007; 59: 87-100 (Pubitemid 46770901)
85. Whelan J. First clinical data on RNAi. Drug Discov Today 2005; 10: 1014-5 (Pubitemid 41074135)
86. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 21]
87. ZaBeCor news [online]. Available from URL: http://www.zabecor.com/news/ news092209.php [Accessed 2012 Apr 21]
88. Dessy A, Gorman J. The emerging therapeutic role of RNA interference in disorders of the central nervous system. Clin Pharmacol Ther 2011; 89: 450-4
89. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs. Biodrugs 2010; 24: 195-205